KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Total Debt (2022 - 2025)

Adaptive Biotechnologies' Total Debt history spans 4 years, with the latest figure at $131.2 million for Q4 2025.

  • For Q4 2025, Total Debt fell 1.55% year-over-year to $131.2 million; the TTM value through Dec 2025 reached $131.2 million, down 1.55%, while the annual FY2025 figure was $131.2 million, 1.55% down from the prior year.
  • Total Debt for Q4 2025 was $131.2 million at Adaptive Biotechnologies, roughly flat from $131.8 million in the prior quarter.
  • Across five years, Total Debt topped out at $133.6 million in Q2 2025 and bottomed at $125.4 million in Q4 2022.
  • The 4-year median for Total Debt is $131.8 million (2025), against an average of $131.4 million.
  • The largest annual shift saw Total Debt increased 4.23% in 2023 before it dropped 1.55% in 2025.
  • A 4-year view of Total Debt shows it stood at $125.4 million in 2022, then grew by 4.23% to $130.7 million in 2023, then rose by 2.0% to $133.3 million in 2024, then fell by 1.55% to $131.2 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Total Debt are $131.2 million (Q4 2025), $131.8 million (Q3 2025), and $133.6 million (Q2 2025).